OSE Immunotherapeutics Stock OTC Markets
Stocks
ORPHF
FR0012127173
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 87.82M 100M 80.89M 75.08M 143M 9.57B 145M 968M 377M 4.7B 377M 368M 16.28B | P/E 2026 * |
-2.87x | P/E 2027 * | -3.29x |
|---|---|---|---|---|---|
| Enterprise Value | 129M 147M 118M 110M 209M 14.01B 212M 1.42B 552M 6.88B 551M 539M 23.84B | EV / Sales 2026 * |
26.2x | EV / Sales 2027 * | 14.3x |
| Free-Float |
74.23% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: OSE Immunotherapeutics
| 1 day | +190.00% |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Bozec
CEO | Chief Executive Officer | - | 02/10/2025 |
Thomas Gidoin
DFI | Director of Finance/CFO | 43 | 20/08/2025 |
Silvia Comis
CTO | Chief Tech/Sci/R&D Officer | - | 20/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Maryvonne Hiance
BRD | Director/Board Member | 77 | 31/05/2016 |
Brigitte Dreno
BRD | Director/Board Member | 73 | 14/06/2017 |
| Director/Board Member | - | 22/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +190.00% | +143.99% | - | - | 100M | |
| +1.08% | +7.56% | +4.01% | +9.84% | 49.92B | |
| +0.18% | -1.55% | +417.15% | +623.82% | 40.23B | |
| -0.23% | +7.05% | +27.36% | -4.94% | 34.55B | |
| +4.29% | +6.92% | +28.66% | +63.68% | 33.09B | |
| -4.19% | +6.03% | +3.76% | +32.17% | 27.51B | |
| -1.76% | +2.36% | - | - | 17.05B | |
| +0.71% | +4.84% | +75.79% | +139.58% | 15.92B | |
| -0.95% | +0.76% | +13.97% | +21.59% | 13.86B | |
| +2.49% | +4.00% | +100.86% | +100.96% | 13.52B | |
| Average | +19.10% | +5.72% | +83.95% | +123.34% | 27.3B | |
| Weighted average by Cap. | +0.28% | +6.43% | +95.12% | +141.27% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.9M 5.59M 4.51M 4.19M 7.96M 534M 8.06M 54.02M 21.03M 262M 21.01M 20.55M 908M | 10.53M 12.02M 9.7M 9M 17.1M 1.15B 17.33M 116M 45.18M 563M 45.15M 44.16M 1.95B |
| Net income | -30.59M -34.92M -28.17M -26.15M -49.66M -3.33B -50.33M -337M -131M -1.64B -131M -128M -5.67B | -21.47M -24.51M -19.77M -18.35M -34.85M -2.34B -35.32M -237M -92.11M -1.15B -92.05M -90.03M -3.98B |
| Net Debt | 40.79M 46.58M 37.57M 34.87M 66.22M 4.44B 67.12M 450M 175M 2.18B 175M 171M 7.56B | 63.08M 72.03M 58.1M 53.93M 102M 6.87B 104M 696M 271M 3.37B 271M 265M 11.69B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
